Clinical trial Recruiting at 1 site Observational Ages 18 and up

Study of hearing and balance issues in DFNA9 patients

Official title: Evaluation of Hearing and Vestibular Function in Presymptomatic and Symptomatic DFNA9 Patients Carrying the Pro51Ser (P51S) Mutation in the COCH Gene.

Run by Jessa Hospital · NCT03716908 · Data updated 2026-11-12

This study is testing how hearing and balance issues are linked to a specific gene mutation in people with DFNA9, including those who may not yet show symptoms, to better understand their experiences and challenges.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment70 (estimated)
SponsorJessa Hospital
Academic / other
Locations1 site (Antwerp)
StatusRecruiting
StartedJune 1, 2018
Main results expectedFebruary 15, 2020
Study endsNovember 30, 2026
Registry record updatedOctober 28, 2021
Trial IDNCT03716908 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals aged 18 and older who are family members of probands carrying the P51S COCH mutation.

Probably not a fit

Patients who may not benefit include those under 18 years old, individuals with other vestibular diseases, or those who have undergone relevant surgeries.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the correlation between genotype and phenotype in patients with DFNA9, focusing on both presymptomatic and symptomatic carriers of the Pro51Ser mutation in the COCH gene. By utilizing a comprehensive vestibular test battery, including advanced assessments like videonystagmography and vestibular-evoked myogenic potentials, the study seeks to provide a more accurate evaluation of vestibular dysfunction. The research will also incorporate pure tone audiometry and various questionnaires to assess the impact on quality of life and balance. This approach aims to fill the gaps left by previous studies that did not adequately represent presymptomatic individuals or utilize a complete vestibular assessment.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of vestibular dysfunction in DFNA9 patients, enhancing their quality of life.

How similar studies have gone: While previous studies have explored genotype-phenotype correlations in DFNA9, this study's comprehensive approach with modern vestibular testing is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* subject must be 18 year of older
* subject is a family member of the family pedigree's proband(s) carrying a P51S COCH mutation

Exclusion Criteria:

* subject is younger than 18 years
* subject is not a family member of the pedigree's proband(s) carrying a P51S
* subject cannot undergo investigations (medical and/or mental reasons)
* subject is not willing to be enrolled into the study
* subject suffers other concomitant middle or inner ear disease
* subject has undergone middle ear or inner ear surgery
* subject suffers other concomitant vestibular disease than DFNA9
* subject has undergone vestibular surgery or other non-invasive vestibular treatment (gentamicin intratympanal injections for example)

Where it's running

  • University of Antwerp
    Antwerp, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.